NASDAQ:PBLA Panbela Therapeutics (PBLA) Stock Price, News & Analysis $0.34 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.31▼$0.3850-Day Range$0.34▼$0.4552-Week Range$0.30▼$40.80Volume28,439 shsAverage Volume16,539 shsMarket Capitalization$1.18 millionP/E RatioN/ADividend YieldN/APrice Target$500.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Panbela Therapeutics alerts: Email Address Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Panbela Therapeutics Stock (NASDAQ:PBLA)Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Read More PBLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBLA Stock News HeadlinesJune 24, 2024 | globenewswire.comPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationMay 25, 2024 | nasdaq.comPanbela Therapeutics Inc. (PBLA) Insider ActivityJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 17, 2024 | msn.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 16, 2024 | uk.finance.yahoo.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 15, 2024 | globenewswire.comPanbela Provides Business Update and Reports Q1 2024 Financial ResultsJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 6, 2024 | finance.yahoo.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 6, 2024 | globenewswire.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 1, 2024 | globenewswire.comPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024April 30, 2024 | globenewswire.comAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekApril 22, 2024 | globenewswire.comPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025April 18, 2024 | marketwatch.comPanbela Applies to List on CBOEApril 18, 2024 | globenewswire.comPanbela Announces Poster Presentation at American Association for Cancer Research:April 17, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB MarketApril 16, 2024 | finance.yahoo.comPanbela Announces Transfer to OTCQB MarketSee More Headlines Receive PBLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBLA CUSIPN/A CIK1029125 Webwww.panbela.com Phone(952) 479-1196FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$500.00 High Stock Price Target$500.00 Low Stock Price Target$500.00 Potential Upside/Downside+147,829.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($280.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70,194.55% Return on Assets-207.79% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.37) per share Price / Book-0.02Miscellaneous Outstanding Shares3,481,000Free Float3,481,000Market Cap$1.18 million OptionableNot Optionable Beta1.58 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Jennifer K. Simpson CRNP (Age 56)M.S.N., Ph.D., CEO, President & Director Comp: $527kMs. Susan Horvath (Age 65)VP of Finance, CFO, Secretary & Treasurer Comp: $452.39kMs. Tammy GroeneVice President of OperationsDr. Elizabeth Bruckheimer Ph.D.VP & Chief Scientific OfficerKey CompetitorsLixte BiotechnologyNASDAQ:LIXTHoth TherapeuticsNASDAQ:HOTHBiofronteraNASDAQ:BFRIBioCardiaNASDAQ:BCDABright Minds BiosciencesNASDAQ:DRUGView All CompetitorsInsidersGoldman Sachs Group IncSold 3,643 sharesTotal: $51,730.60 ($14.20/share)View All Insider Transactions PBLA Stock Analysis - Frequently Asked Questions How have PBLA shares performed this year? Panbela Therapeutics' stock was trading at $18.30 at the beginning of 2024. Since then, PBLA stock has decreased by 98.2% and is now trading at $0.3380. View the best growth stocks for 2024 here. How were Panbela Therapeutics' earnings last quarter? Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its earnings results on Wednesday, May, 15th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $1.05. When did Panbela Therapeutics' stock split? Panbela Therapeutics shares reverse split before market open on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Panbela Therapeutics? Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PBLA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.